Jorge Sanchez, Andrés Sánchez, Yaquelin Padilla, Adriana Lorduy, Marlon Munera, Claudia Baena, Carlos Bernal, Juan Urrego
Journal: F1000Research 2024;13():358
PMID: 39310813
BACKGROUND
Atopic dermatitis (AD) is a chronic inflammatory skin condition that has a significant impact on quality of life. The immune response and allergy symptoms in AD are triggered by the recognition of specific allergens by IgE antibodies. Cross-reactivity can lead to auto-IgE responses, potentially worsening AD symptoms. Our research aimed to enhance our understanding of allergenic sources, including A. fumigatus, and their role in AD. We focused on molecular mimicry between human AQP3 and A. fumigatus aquaporin.
METHODS
In our in-silico analysis, we compared the amino acid sequences of human aquaporin 3 (AQP3) and A. fumigatus aquaporin with 25 aquaporins from various allergenic sources, sourced from the UniProt and NCBI databases. Phylogenetic relationship analysis and homology-based modeling were conducted. We identified conserved antigenic regions located within the 3D structures.
RESULTS
The global identity levels among the studied aquaporins averaged 32.6%. One antigenic site exhibited a remarkable local region, with a conserved identity of 71.4%. We categorized the aquaporins into five monophyletic clades (A-E), with group B showing the highest identity (95%), including six mammalian aquaporins, including AQP3. When comparing aquaporins, the highest identity was observed with at 35%. Both human and A. fumigatus aquaporins have three linear and three discontinuous epitopes.
CONCLUSIONS
We identified potential linear and conformational epitopes of AQP3, indicating a possible molecular mimicry between humans and aquaporins. This suggests autoreactivity and potential cross-reactivity, although further validation using in vitro and in vivo experiments is required.
Copyright: © 2024 Sánchez A et al.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.